4月9日，港股上市公司荣昌生物（09995）股价表现强劲，盘中大涨11.51%，引发投资者广泛关注。截至盘中15时35分，该股报价已达到创近期新高。
此次股价大涨主要源于公司重磅新药的积极进展。荣昌生物于今日宣布，其自主研发的BLyS/APRIL双靶点融合蛋白创新药泰它西普（telitacicept，RC18）在治疗全身型重症肌无力（gMG）的3期临床研究中取得了突破性进展。研究数据显示，经过24周的泰它西普治疗后，98.1%的患者重症肌无力日常活动评分（MG-ADL）改善≥3分，87%的患者定量重症肌无力评分（QMG）改善≥5分，具有显著的临床意义。这一重要成果以"最新突破性研究"的形式在美国神经病学学会（AAN）年会上进行了口头报告，引起了业界的高度关注。
值得一提的是，泰它西普用于治疗全身型重症肌无力的上市申请已于去年10月获得中国药品监督管理局药品审评中心（CDE）受理，并被纳入优先审评通道。公司预计，该药有望于今年第二季度在中国获批上市。这一利好消息进一步增强了投资者对荣昌生物未来发展前景的信心，推动了股价的显著上涨。随着新药上市进程的推进，市场将持续关注荣昌生物的后续发展动向。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.